Revenue trends

Alkermes (ALKS) reported its third-quarter financial results on October 23. It generated net revenues of $248.7 million compared to $217.4 million in the third quarter of 2017. That was a 14% YoY (year-over-year) growth.

Its manufacturing and royalty revenues were $116.4 million, a 5% YoY decline. Those revenues came primarily from Risperdal Consta, Invega Sustenna/Xeplion, and Invega Trinza.

Alkermes in the Third Quarter: A Performance Overview

Alkermes reported net revenues from product sales of $166.3 million compared to $96.7 million in the third quarter of 2017, reflecting a 20% YoY growth.

In the third quarter, Alkermes generated revenues of $16.3 million from R&D (research and development) collaborations. Those revenues include $15.7 million from Biogen (BIIB) for an R&D collaboration related to BIIB098 (diroximel fumarate), an investigational drug.

Product revenue trends

In the third quarter, Alkermes’s (ALKS) Vivitrol and Aristada generated revenues of $79.9 million and $36.1 million, respectively. That compares to $69.2 million and $24.5 million, respectively, in the third quarter of 2017 and ~15% and ~48% YoY growth, respectively.

Peer comparisons

Alkermes’s peers in the biopharmaceuticals market include Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN), and Neurocrine Biosciences (NBIX). They reported revenues of $117.75 million, $1.6 billion, and $96.91 million, respectively, in the second quarter of 2018. Ionis Pharmaceuticals and Neurocrine Biosciences had ~13.05% and ~9.38% YoY growth, respectively. Neurocrine Biosciences’ net revenues grew from $6.3 million in the second quarter of 2017 to $96.91 million in the second quarter of 2018.

Wall Street analysts anticipate that in the third quarter, Ionis Pharmaceuticals, Regeneron Pharmaceuticals, and Neurocrine Biosciences will have revenues of $152.68 million, $1.6 billion, and $151.83, respectively. That represents YoY growth of ~26.28%, ~9.39%, and ~150%, respectively.

The revenue growth of Alkermes, Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN), and Neurocrine Biosciences (NBIX) could boost the First Trust NYSE Arca Biotechnology Index Fund (FBT). They make up ~3.38%, ~3.82%, ~3.75%, and ~3.73%, respectively, of FBT’s total portfolio holdings.

Latest articles

WeWork is gearing up for an IPO. On Wednesday, the company made its IPO filing with the SEC public and expects to garner $3.5 billion from its IPO.

After FCC Chairman Ajit Pai recommended the approval of the T-Mobile–Sprint merger, Representative David Cicilline urged the FCC to allow public comment.

Cresco Labs (CRLBF) is set to report its Q2 earnings on August 21 after the market closes. The company's stock fell 5.3% yesterday.

Cannabis stocks mostly traded in positive territory today. Supreme Cannabis (FIRE) and Aurora Cannabis (ACB) rose about 9.5% and 5.5%, respectively.

NVIDIA (NVDA) stock soared 6% in today’s trading session as its Q2 earnings for fiscal 2020 beat estimates. However, its guidance missed estimates.

Nio Inc. (NIO) has disrupted the automotive space since 2014 but only made waves in the market since its IPO. Investors have suffered numerous setbacks.